LEADER 04688nam 22006135 450 001 9910253884803321 005 20251116155317.0 010 $a3-319-32232-X 024 7 $a10.1007/978-3-319-32232-2 035 $a(CKB)3710000000685973 035 $a(EBL)4530825 035 $a(DE-He213)978-3-319-32232-2 035 $a(MiAaPQ)EBC4530825 035 $a(PPN)194079414 035 $a(EXLCZ)993710000000685973 100 $a20160521d2016 u| 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aAlgae-Based Biopharmaceuticals /$fby Sergio Rosales-Mendoza 205 $a1st ed. 2016. 210 1$aCham :$cSpringer International Publishing :$cImprint: Springer,$d2016. 215 $a1 online resource (172 p.) 300 $aDescription based upon print version of record. 311 08$a3-319-32230-3 320 $aIncludes bibliographical references at the end of each chapters and index. 327 $aThe Biopharmaceuticals Field and Algae as Expression Hosts -- Genetic Engineering Approaches for Algae -- Algae-made Vaccines Targeting Human Diseases -- Algae-made Vaccines Targeting Animal Pathogens -- Algae-made Antibodies and Immunotoxins -- Algae-made Cytokines and Growth Factors -- Other Biopharmaceuticals Produced in Algae -- Algae-made Nutraceuticals -- Perspectives for the Algae-made Biopharmaceuticals Field. 330 $aThis book constitutes a key reference on the use of algae in the BFs production field; providing an updated outlook on the achievements accomplished thus far and transmitting a prospective view for this biotechnological application. This book provides a detailed description of the technology as well as an updated outlook of the strides achieved thus far in the field of algae-based biopharmaceuticals. Algae constitute attractive expression hosts for the production of recombinant proteins with medical applications. Among the features that make them attractive candidates are: low cost, fast growth, wide biosynthetic capacity, and absence of human pathogens; which constitute substantial advantages with respect to bacterial and mammalian systems. First, the features of algae as convenient hosts for the production of BFs are analyzed in terms of production costs, biosynthetic capacity, and safety (Chapter 1). Second, the genetic engineering tools for algae-species are described. Nuclear and chloroplast-based expression approaches are analyzed and compared in terms of biosynthetic advantages, gene expression complexity, and DNA transfer approaches (Chapter 2). In the following sections, chapters 3 to 7, the state of the art on producing distinct types of BFs in algae species is presented. Although this book is mainly focused on BFs, considering that the production of compounds with health-promoting properties are achieved using genetically-engineered algae strains, chapter 8 deals with nutraceuticals. In the ninth chapter, the developments reported thus far are placed in perspective and challenges for the field are discussed. Critical future prospects comprise the following: optimizing large-scale production in bioreactors, implementing glycoengineering approaches, optimizing nuclear expression, exploring new approaches for oral delivery, and implementing regulatory frameworks to accomplish technology transfer and regulatory approval of algae-made BFs. 606 $aPlant breeding 606 $aAquatic ecology 606 $aPharmaceutical technology 606 $aPlant anatomy 606 $aPlants$xDevelopment 606 $aPlant Breeding/Biotechnology$3https://scigraph.springernature.com/ontologies/product-market-codes/L24060 606 $aFreshwater & Marine Ecology$3https://scigraph.springernature.com/ontologies/product-market-codes/L19066 606 $aPharmaceutical Sciences/Technology$3https://scigraph.springernature.com/ontologies/product-market-codes/B21010 606 $aPlant Anatomy/Development$3https://scigraph.springernature.com/ontologies/product-market-codes/L24019 615 0$aPlant breeding. 615 0$aAquatic ecology. 615 0$aPharmaceutical technology. 615 0$aPlant anatomy. 615 0$aPlants$xDevelopment. 615 14$aPlant Breeding/Biotechnology. 615 24$aFreshwater & Marine Ecology. 615 24$aPharmaceutical Sciences/Technology. 615 24$aPlant Anatomy/Development. 676 $a570 700 $aRosales Mendoza$b Sergio$4aut$4http://id.loc.gov/vocabulary/relators/aut$0781335 906 $aBOOK 912 $a9910253884803321 996 $aAlgae-Based Biopharmaceuticals$92533153 997 $aUNINA